HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J/Merck Bolsters Heartburn Lineup With Maximum Strength Pepcid AC

This article was originally published in The Tan Sheet

Executive Summary

New heartburn prevention/relief product Maximum Strength Pepcid AC will hit shelves Oct. 17, following FDA approval of the new dosage Sept. 24, according to Johnson & Johnson/Merck

You may also be interested in...



Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch

Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year

J&J, Schering OTC Advertising Outpaced DTC Spending In 2003

Johnson & Johnson spent approximately 40% more on OTC drug advertising in the first nine months of 2003 than on direct-to-consumer prescription drug advertising

Rolaids Line Expands Into Gas Relief With Multi-Symptom Extension

Pfizer is positioning new Rolaids Multi-Symptom line extension as handling gas as well as heartburn in comparison to GlaxoSmithKline's Tums in spots that broke November 17

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS129725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel